In the specific context of cancer, RAF dimerization inhibitors combine a beneficial cell autonomous effect on tumor proliferation, by reducing the activity of the ERK pathway, with the normalization of vascular permeability, allowing for better drug delivery. This evidence concerns the gene RAF1 and cancer.